PPD’s Post

In the light of recent draft guidances from FDA on core patient-reported outcomes (PROs) in cancer trials, and on dose optimization in oncology drug development (resulting from the Project Optimus initiative) – thoughtful collection and interpretation of patient experience data in oncology clinical research is becoming even more critical. 💡 Explore use cases and gain practical tips for implementing PROMs throughout oncology in our webinar on: ✍ 8th February at 4pm GMT https://bit.ly/47mhvQZ

At Aixial Group we empower sponsors with our people and processes to enable patients to access better treatments across the globe. Meet some of the people behind the success of your clinical trials. #AixialGroup #oncology #rarediseases #CRO #ClinicalDevelopment #clinicaltrials #Medical #Vigilance #MedicalWriting #DataManagement #Statistics #QualityAssurance #RegulatoryAffairs #ClinicalSupply

#ProjectFrontRunner represents a paradigm shift in conventional methods of #oncology drug development. It encourages drug companies to accelerate investigations of novel therapies in earlier metastatic treatment settings. Read more about how this initiative aims to offer patients earlier access to safe and effective therapies at the initial course of their disease. https://bit.ly/3XLbr32 #clinicalresearch #precisiononcology

🔬 Oncology clinical trial participants bear significant burdens. It's crucial for professionals planning studies to prioritize their well-being. Patients, often unwell even before trials start, are impacted by every aspect—including required technologies. One solution? Prioritize patient-centered tech. 📊 Join this upcoming webinar with YPrime, where a former participant and cancer survivor, now a pharmaceutical R&D leader, shares her journey. Panelists will explore patient technologies like eCOA and connected devices, emphasizing how positive patient experiences benefit all stakeholders 🔗 REGISTER HERE: https://buff.ly/4a9pGC9 🌟 Featured speakers: Rosie Filling Donna Mongiello, RN, BSN Terry Rehm #DrugDevelopment #ClinicalResearch #Oncology #ClinicalData #OncologyTrials #eCOA #TherapeuticAreas #eCOATechnology

As Lonnie navigated through a maze of medical terms while searching for a prostate clinical trial, the need for simplicity became clear. Support myTRIAList in bridging the gap between medical jargon and patient comprehension by sponsoring a searchable plain language trial-specific overview video in the myTRIAList Trial Finder. Learn more here: https://buff.ly/4c5nbkz #ProstateCancer #Healthcare #MedEd #ClinicalTerms #Oncology #PatientExperience #Pharma #Biotech CancerCare

Lots of exciting insights with oncology manufacturer benchmarking rating on customer experience along with insights on access challenges (e.g., maximizer/accumulator, IRA, AFP) impact on HCPs, field utilization, advances with AI, patient attrition drivers, etc. The study is the most comprehensive of its kind and is bringing the customer voice to strategic decision-making! (see https://lnkd.in/edZbfiUE for more info) #pharma #CustomerExperience #Benchmarking #PURE

For patients, drug development timelines are not fast enough. At Viracta, we are actively working to accelerate our clinical trial timelines to meet the needs of patients living with EBV-associated cancer today. #TeamViracta will be carrying this early 2024 energy throughout the year.  Read more about our clinical trial updates and outlook for 2024 here 👇 https://lnkd.in/gdCzUdxc #news #EBV #lymphoma #clinicaltrials

Lots going on in the #radiopharmaceuticals and #targetedradiotherapy field at the moment! From successful #acquisitions to challenges with #supply constraints impacting clinical trial enrollment to advances in #diagnostics to #actinium-225 based therapies showing more potential as a serious contender to some of the established #lutetium-117 based therapies. Looking forward to seeing how this space evolves in the coming years and the potential impact in #oncology and beyond!

In this edition of the New Medicines, Novel Insights newsletter, Martin Roessner, Corporate VP of Biostatistics at Parexel, discusses the potential for oncology trial acceleration through the implementation of flexible trial designs and master protocols. Learn how deviations from traditional approaches can increase efficiencies as Martin reviews key trial considerations, the case for real-world data (RWD), best practices, and potential use cases. Read the full article and subscribe to get the latest #NovelInsights each week! #Oncology #ClinicalInnovation #InnovativeTrial #RWD

In this position paper, Marc argues that #Oncology is the next therapeutic frontier for the application of value-based agreements. As a country and society, we must move towards value-based health - from therapeutics to the provisioning of healthcare services. Thought leaders like Peter have been discussing the societal value and importance of therapeutics for some time. It's now time to put our money where value is created, not destroyed. #NoPatientLeftBehind